ChemoCentryx has been granted a patent for a method to treat pancreatic cancer by administering specific compounds and pharmaceutical combinations. The method aims to control adenocarcinoma by regulating oncogenes, tumor suppressor genes, and signaling proteins. GlobalData’s report on ChemoCentryx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights ChemoCentryx Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on ChemoCentryx, was a key innovation area identified from patents.

Treatment of pancreatic cancer using pharmaceutical combinations

Source: United States Patent and Trademark Office (USPTO). Credit: ChemoCentryx Inc

A recently granted patent (Publication Number: US11890276B2) discloses a method for controlling adenocarcinoma in patients by administering a pharmaceutical combination containing a compound of Formula I. The compound's specific structure is defined by various parameters, including the presence of halogen or methyl groups in R1, halogen or C1-6 haloalkyl in R2, and hydrogen in R4, among others. The method aims to provide benefits such as tumor size reduction, suppression of tumor growth, increased survival rates, and various other positive outcomes related to pancreatic adenocarcinoma.

Furthermore, the patent outlines the use of additional therapeutic compounds in combination with the Formula I compound, including a wide range of established pharmaceuticals like gemcitabine, paclitaxel, and FOLFIRINOX. The administration of the compound can be oral, once or twice a day, with specific dosage ranges between 50 mg to 300 mg, with a preferred effective amount of 150 mg. The patent's comprehensive list of additional therapeutic compounds covers a vast array of established cancer treatments, showcasing the potential for combination therapies to enhance the efficacy of adenocarcinoma treatment. This patent provides a detailed framework for a method that could significantly impact the management and outcomes of patients suffering from various forms of adenocarcinoma.

To know more about GlobalData’s detailed insights on ChemoCentryx, buy the report here.

This content was updated on 25 January 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies